Table 4.
Estimated hazard ratios and 95% confidence intervals for the relationship between PD-L1 and IDO and overall survival (N=93)
| Total | Low CD8 | High CD8 | Low Fox3p | High Fox3p | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||
| Cases (Deaths) | HR (95% CI)a | Cases (Deaths) | HR (95% CI)a | Cases (Deaths) | HR (95% CI)a | Cases (Deaths) | HR (95% CI)a | Cases (Deaths) | HR (95% CI)a | |
| PD-L1 Tumor | ||||||||||
| Negative | 66 (33) | 1.00 (Referent) | 36 (16) | 1.00 (Referent) | 30 (17) | 1.00 (Referent) | 35 (16) | 1.00 (Referent) | 31 (17) | 1.00 (Referent) |
| Positive | 27 (7) | 0.61 (0.26–1.41) | 9 (4) | 0.81 (0.26–2.51) | 18 (3) | 0.19 (0.04–0.94) | 10 (3) | 0.45 (0.12–1.60) | 17 (4) | 0.89 (0.26–3.02) |
| PD-L1 Immune | ||||||||||
| Negative | 23 (11) | 1.00 (Referent) | 17 (8) | 1.00 (Referent) | 6 (3) | 1.00 (Referent) | 15 (7) | 1.00 (Referent) | 8 (4) | 1.00 (Referent) |
| Positive | 70 (29) | 1.43 (0.68–3.00) | 28 (12) | 1.33 (0.50–3.53) | 42 (17) | 0.90 (0.23–3.44) | 30 (12) | 1.42 (0.49–4.14) | 40 (17) | 1.22 (0.40–3.67) |
| IDO Tumor | ||||||||||
| Negative | 36 (20) | 1.00 (Referent) | 23 (12) | 1.00 (Referent) | 13 (8) | 1.00 (Referent) | 20 (11) | 1.00 (Referent) | 16 (9) | 1.00 (Referent) |
| Positive | 57 (20) | 0.79 (0.41–1.51) | 22 (8) | 0.83 (0.32–2.16) | 35 (12) | 0.56 (0.21–1.48) | 25 (8) | 0.70 (0.25–1.94) | 32 (12) | 0.67 (0.26–1.74) |
| IDO Immune | ||||||||||
| Negative | 41 (19) | 1.00 (Referent) | 27 (14) | 1.00 (Referent) | 14 (5) | 1.00 (Referent) | 23 (11) | 1.00 (Referent) | 18 (8) | 1.00 (Referent) |
| Positive | 52 (21) | 1.11 (0.57–2.17) | 18 (6) | 0.86 (0.32–2.32) | 34 (15) | 1.03 (0.34–3.13) | 22 (8) | 0.94 (0.35–2.50) | 30 (13) | 0.99 (0.36–2.70) |
a
Adjusted for age at diagnosis, stage, region of residence, and residual disease.